CBAK Energy Signs 12 GWh Sodium-Ion Deal in Nanjing

CBAK Energy Technology Limited (NASDAQ: CBAT) announced on 24 September 2026 that it signed an investment agreement with the Nanjing Gaochun Economic Development Zone to research, develop and manufacture large cylindrical sodium-ion cells and integrated battery systems in Nanjing, Jiangsu Province. The project would add 12 GWh of annual cell capacity, and the company separately targets 6 GWh more at its existing Nanjing plant by year-end 2026, taking that site from 4.5 GWh to 10.5 GWh.

The company said the 12 GWh project is planned for the second half of 2027, subject to securing financing.

Context — Why a 12 GWh Sodium-Ion Agreement Matters Now

CBAK's existing Nanjing plant runs 4.5 GWh of annual Model 32140 cell capacity. Adding 6 GWh there more than doubles the site, and it is the nearer-term, better-funded leg of the announcement. The 12 GWh agreement is the longer-dated piece and carries no disclosed capital cost.

For scale, 12 GWh of annual cell output is a mid-single-digit share of global battery cell additions in a typical year — meaningful for a company of CBAT's size, marginal for the industry's total. The company did not disclose the investment amount, financing structure, or the split of government support versus company capital.

The catalyst chain runs through demand, not policy. CBAK attributes the 6 GWh expansion to strong demand for Model 60150 large cylindrical cells, and says it may swap one planned 60150 line for a 32140 line if 32140 demand holds up. Chemistry choice on the 12 GWh project is explicitly left open.

The location matters. Nanjing Gaochun is an established manufacturing zone, and CBAK already runs cell production, R&D and sales from Nanjing, Dalian and Shangqiu, with raw materials in Shaoxing. The agreement extends an existing footprint rather than opening a new region.

Sodium-ion cells have drawn attention as a cheaper, lithium-free alternative, but commercial adoption has lagged lithium-ion on energy density and cycle life. CBAK's decision to design lines that can run either chemistry is a hedge against that adoption curve, not a bet on it.

Data — What the Numbers Show

Metric	Existing Nanjing	After 6 GWh expansion
Annual cell capacity	4.5 GWh	10.5 GWh
Estimated annual revenue	Not disclosed	RMB 2.4–2.7bn (US$356–400m)

The 6 GWh addition implies roughly RMB 400–600m of annual revenue per incremental GWh at full utilization, assuming all output sells. CBAK states the estimate assumes a full year at full capacity with all output sold, and that it is not guidance.

The 12 GWh project carries a larger headline number: RMB 4.8–5.0bn (US$712–741m) of estimated annual revenue at full capacity, benchmarked to current lithium-ion cell market prices. That works out to roughly RMB 400–417m per GWh — slightly below the 6 GWh project's implied range, consistent with the sodium-ion option and phased build.

Neither figure is contracted sales. CBAK says actual revenue depends on project completion, customer qualification, product mix, market pricing, utilization, yields and sales.

The stock context: CBAT is the first Chinese lithium battery manufacturer listed on Nasdaq, a listing it has held since January 2006. The company did not disclose current order book, customer names, or capex for either project.

Analysis — What It Means for Battery and Materials Names

The near-term read is capacity, not chemistry. A doubling of an existing plant is executable and revenue-generating sooner than a greenfield 12 GWh build that depends on financing not yet secured. The 12 GWh sodium-ion agreement is closer to an option on a second chemistry than a committed production plan.

Second-order effects land on the large cylindrical cell supply chain. CBAK competes in a segment where 32140 and 60150 formats serve light electric vehicles, energy storage and power tools. Incremental GWh from a Chinese mid-cap adds marginal supply pressure to those formats, though 10.5 GWh total is small against the global cylindrical market.

The limitation is financing. CBAK explicitly conditions the 12 GWh project on securing funds and advancing in phases. Without disclosed terms, there is no way to assess whether the capital is available, what it costs, or how dilution is handled. A phased structure also means any revenue estimate is back-end loaded.

Sodium-ion upside depends on adoption, and the company acknowledges this by designing lines for either chemistry. If sodium-ion economics improve, CBAK has optionality; if they do not, the same lines run lithium-ion.

Positioning: CBAT is a small-cap with a Nasdaq listing, so flow is retail- and event-driven around announcements rather than institutional. The stock's reaction will hinge on whether investors read the 6 GWh expansion as near-term revenue or the 12 GWh agreement as financing risk.

Outlook — What to Watch Next

Three catalysts define the timeline. First, the 6 GWh expansion is targeted for the second half of 2026, with the company's stated goal of 10.5 GWh total annual capacity by year-end 2026. Second, the 12 GWh project is planned for the second half of 2027, contingent on financing. Third, the production-line configuration — one 60150 line plus one 32140 line, or two 60150 lines — may be adjusted as customer demand evolves.

Investors should watch for any disclosure of financing terms, customer qualification wins, or an order book for the 60150 format. The company has not disclosed capex, so cash flow and balance-sheet capacity are the swing variables.

Levels: CBAT trades as a low-float small-cap, so price action on announcements is typically volatile. On the operational side, the number to track is capacity utilization at Nanjing — whether the 4.5 GWh base is fully sold before 6 GWh is added.

Frequently Asked Questions

What does CBAK's 12 GWh sodium-ion agreement actually commit the company to?

The agreement with the Nanjing Gaochun Economic Development Zone covers research, development and manufacture of large cylindrical sodium-ion cells and integrated battery systems. It is an investment agreement, not a financed construction contract. CBAK plans to advance the project in the second half of 2027, subject to securing financing, and says development would proceed in phases based on financing, customer demand and project readiness. No capital cost was disclosed.

What is the difference between the 6 GWh and 12 GWh projects?

The 6 GWh expansion is at CBAK's existing Nanjing facility, targeted for the second half of 2026, and would lift annual cell capacity there from 4.5 GWh to 10.5 GWh. The 12 GWh project is a separate, larger build planned for the second half of 2027 and conditioned on financing. The 6 GWh is nearer-term and tied to Model 60150 demand; the 12 GWh can run sodium-ion or lithium-ion.

How do CBAK's revenue estimates compare to its current scale?

CBAK estimates the 6 GWh expansion could generate RMB 2.4–2.7bn (US$356–400m) annually and the 12 GWh project RMB 4.8–5.0bn (US$712–741m), both at full capacity with all output sold. The company states these are not guidance, not contracted sales, and assume a full year of operation at full capacity. Actual revenue depends on completion, qualification, pricing, utilization and yields.

Bottom Line

CBAK's near-term capacity doubling is executable; the 12 GWh sodium-ion project remains an unfinanced option.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.